Ten drugs were classified as low or no added therapeutic benefit compared with alternatives, accounting for $6.7 billion in ...

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Cardiff ...

Oncogenic proteins are essential for the development and spread of tumors, making cancer a significant worldwide health ...

The battle against drug resistance in lung cancer therapy remains a critical issue in oncology, with resistance mechanisms ...

One area we have the best evidence for is that "bug drugs" may help the body fight cancer by interacting with routinely used immunotherapy drugs. Recent studies have shown encouraging results.

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer. Antibody-drug conjugates, or ADCs, have had a tremendous impact on the ...

Researchers from the University of Texas Health Science Center at San Antonio have developed a drug that more than ... professor and chair of neuro-oncology research with Mays Cancer Center ...

Why ALZpath, GeneDX, 10x Genomics, Protagonist Therapeutics, and Recursion are among the most innovative biotech companies of 2025.

The U.S. Pharmacopeia has published its 2024-2025 Vulnerable Medicines List, identifying 100 drugs at risk of supply disruptions in the U.S. The list includes 49 medications for chronic conditions ...